AHIP Statement On EpiPen Price Increase

posted by Clare Krusing

on August 26, 2016

Today’s announcement from Mylan is a recycled approach to a cost problem that continues to get worse. Here’s a statement from AHIP below —

“We’ve seen this time and time again. Rather than actually taking steps to address the real problem of soaring drug prices, pharma companies try and cover their price hikes through patient assistance programs and co-pay support. None of which will make a drug more affordable for the people who need it most. Exorbitant price increases on prescription drugs are leading to higher premiums and out-of-pocket costs for patients, and pharma companies continue to deny that reality.” – Clare Krusing, AHIP spokeswoman

For more on the backstory with pharma companies’ patient assistance programs, read Bloomberg’s latest piece – “How Big Pharma Uses Charity Programs to Cover for Drug Price Hikes.” Check out AHIP’s infographic below on the price increases on prescription drugs, including EpiPens.


" "